The relative phases of basal ganglia activities dynamically shape effective connectivity in Parkinson’s disease

Hayriye Cagnan,¹,²,³ Eugene Paul Duff⁴ and Peter Brown¹,²

Optimal phase alignment between oscillatory neural circuits is hypothesized to optimize information flow and enhance system performance. This theory is known as communication-through-coherence. The basal ganglia motor circuit exhibits exaggerated oscillatory and coherent activity patterns in Parkinson’s disease. Such activity patterns are linked to compromised motor system performance as evinced by bradykinesia, rigidity and tremor, suggesting that network function might actually deteriorate once a certain level of net synchrony is exceeded in the motor circuit. Here, we characterize the processes underscoring excessive synchronization and its termination. To this end, we analyzed local field potential recordings from the subthalamic nucleus and globus pallidus of five patients with Parkinson’s disease (four male and one female, aged 37–64 years). We observed that certain phase alignments between subthalamic nucleus and globus pallidus amplified local neural synchrony in the beta frequency band while others either suppressed it or did not induce any significant change with respect to surrogates. The increase in local beta synchrony directly correlated with how long the two nuclei locked to beta-amplifying phase alignments. Crucially, administration of the dopamine prodrug, levodopa, reduced the frequency and duration of periods during which subthalamic and pallidal populations were phase-locked to beta-amplifying alignments. Conversely ON dopamine, the total duration over which subthalamic and pallidal populations were aligned to phases that left beta-amplitude unchanged with respect to surrogates increased. Thus dopaminergic input shifted circuit dynamics from persistent periods of locking to amplifying phase alignments, associated with compromised motoric function, to more dynamic phase alignment and improved motoric function. This effect of dopamine on local circuit resonance suggests means by which novel electrical interventions might prevent resonance-related pathological circuit interactions.

1 Medical Research Council Brain Network Dynamics Unit at the University of Oxford, Mansfield Road, OX1 3TH, UK
2 Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, OX3 9DU, UK
3 The Wellcome Trust Centre for Neuroimaging, University College London, Queen Square, London WC1N 3BG, UK
4 FMRIB Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK

Correspondence to: Prof Peter Brown,
Medical Research Council Brain Network Dynamics
Unit at the University of Oxford, Mansfield Road,
OX1 3TH, UK
E-mail: peter.brown@ndcn.ox.ac.uk

Keywords: Parkinson’s disease neurophysiology; beta oscillations; basal ganglia; deep brain stimulation; subthalamic nucleus; clinical neurophysiology

Abbreviations: GP = globus pallidus; LFP = local field potential; PSI = phase synchrony index; STN = subthalamic nucleus
Introduction

Oscillatory activity is ubiquitous in the brain and suspected of playing a key role in neural communication (Buzsáki and Draguhn, 2004). One of the most influential theories suggests that the efficacy of information flow between different brain regions depends on the phase alignment between their intrinsic activities (Fries, 2005, 2009). For an excitatory connection, there will be a phase difference at which one region will optimally excite the other, equivalent to the offset between the two locally synchronized oscillating neuronal populations when they are most depolarized. Conversely, there will be a phase difference at which one region will have least effect on the other; equivalent to the offset between the two locally synchronized oscillating neuronal populations when they are at their most hyperpolarized. In line with the theory, optimal phase alignment between functionally connected cortical regions predicted an increase in correlation between the two regions, with correlation being a proxy for information exchange (Womelsdorf et al., 2007).

The above theory of ‘communication-through-coherence’ proposes maximal effective connectivity and information exchange during optimal phase alignment. However, this may not equate with optimal network performance from the behavioural as opposed to information theoretic perspective. Specifically, what is the effect of persistent optimal phase alignment between two neural populations? Need persistently maximal effective connectivity imply a functionally optimal state? Consider a grandfather clock: both the chime sequence, and the timing of the chime sequence, carry valuable information. The clock would not be informative if the chime sequence was played randomly or was continuous. Here, we test the hypothesis that network performance may deteriorate beyond a certain level of net synchrony (Brittain and Brown, 2014). To this end we explore a model system in which synchronization can be readily shifted between pathological exaggeration and more physiological levels. The model system consists of the basal ganglia in patients with Parkinson’s disease, a condition that, in the untreated state, is dominated by exaggerated synchronization and coherence in the basal ganglia-cortical circuit (Brown et al., 2001; Williams et al., 2002; Weinberger et al., 2006; Pogosyan et al., 2010; Hirschmann et al., 2011; Litvak et al., 2011). Such synchronization is diminished by dopaminergic therapy, in tandem with amelioration of motor deficit (Kühn et al., 2006, 2009; Weinberger et al., 2006; Ray et al., 2008).

We can access synchronized population activity in patients with Parkinson’s disease through local field potential (LFP) recordings acquired through the electrodes intended to deliver therapeutic deep brain stimulation (Levy et al., 2002; Kühn et al., 2005; Weinberger et al., 2006; Yang et al., 2014). Here, we consider archival LFP data from patients simultaneously implanted in the subthalamic nucleus (STN) and the globus pallidus (GP) as part of a previously published therapeutic trial (Peppe et al., 2004). These two nuclei are connected by a direct excitatory projection from the STN to the globus pallidus (Bolam et al., 2000). By contrasting data from Parkinson’s disease patients recorded both OFF and ON dopaminergic medication, we are able to associate different levels of optimal phase alignment between these nuclei with different levels of functional performance of the basal ganglia, as inferred from changing levels of motor impairment with medication.

Our study highlights the dynamic nature of phase alignment between neuronal populations. In particular, the data point to a pathologically exaggerated resonant state in untreated Parkinson’s disease that allows (i) the progressive propagation of beta synchrony through basal ganglia nuclei; and (ii) the settling of coupled oscillators into a regime in which phase differences between them preferentially assume values that favour further feed-forward increase in neural synchrony and correlation in the circuit. The circuit is ‘jammed open’ with diminished capability for task-related variation in effective connectivity. Exogenous dopaminergic stimulation through medication acts to restrain excessive communication-through-coherence, sufficient to improve system performance and alleviate motoric symptoms. Delineating how dopaminergic input achieves this ‘normalization’ of communication can inform the development of novel treatment strategies such as electrical interventions designed to shift neuronal populations away from critical phase alignments.

Materials and methods

Patients and recordings

All patients gave their informed consent to take part in the study, which was approved by the local research ethics committee. Patients were enrolled in a trial of combined pallidal and subthalamic deep brain stimulation and had undergone unilateral or bilateral implantation of deep brain stimulation electrodes into the STN and the globus pallidus interna (Table 1) (Peppe et al., 2004). The permanent quadripolar macroelectrode implanted was model 3387 or model 3389 (Medtronic Neurologic Division) featuring four platinum-iridium cylindrical surfaces (contacts 0–3; 0 the most caudal and 3 the most rostral contact). Techniques to target and implant electrodes have previously been described (Peppe et al., 2004).

Target nuclei were identified by non-telemetric ventriculography. Electrode localization was supported with intraoperative microelectrode recordings and electrical stimulation while the patients lay awake, and was confirmed postoperatively using stereotactic CT or MRI. Mean Unified Parkinson’s disease rating scale (UPDRS) motor scores were 66 (range 51–80) and 12 (range 7–20) OFF and ON medication, respectively (Table 1). Patients took a mean daily dosage of 970 mg of levodopa (range 150–1500 mg) (Table 1). LFP features have been previously described in all but one patient (Brown et al., 2001; Cassidy et al., 2002; Williams et al., 2002; Fogelson et al., 2005; Marreiros et al., 2013).
Recordings were made 3–6 days following surgery while patients were seated on a bed, resting following (i) overnight withdrawal of antiparkinsonian medication, termed OFF drug; and (ii) ~1 h after 200 mg levodopa administration, termed ON drug. LFPs were simultaneously recorded as bipolar signals from deep brain stimulation electrode contact pairs 0–1, 1–2, and 2–3 implanted in the STN and globus pallidus. Signals were amplified and pass band filtered between 1 and 300 Hz, and resampled to a common sampling rate of 1000 Hz.

**Data analysis**

Data were analysed to investigate instantaneous changes in basal ganglia communication ON and OFF dopaminergic medication. LFPs were analysed offline using MATLAB®. De-trending was performed on all recordings by subtracting from each data point the mean of ±1 s long data taken around that point. On average 115 ± 18 (mean ± SEM) seconds of data were analysed.

**Contact pair selection**

The bipolar contact pair of the subthalamic electrode that showed the highest power in the beta frequency band (15–30 Hz) OFF medication was selected for further analysis. This selection was based on the fact that STN activity in the beta band (i) correlates with the akinesia and rigidity observed in Parkinson’s disease; (ii) is greatest in the motor region of the STN; and (iii) reflects synchronization in neural elements in this frequency range (Hammond et al., 2007). The bipolar contact pair of the pallidal electrode showing the highest coherence with the selected subthalamic contact pair OFF medication was also selected for further analysis. Note that in the present study, we focus on interactions through the excitatory projection from STN to globus pallidus, and thereby do not differentiate between pallidal contacts in the external and internal part of the globus pallidus. For one subject there was no clear peak in the STN in the beta frequency band, and so the STN and globus pallidus bipolar contact pair combination exhibiting the highest coherence in the beta band was chosen for further analysis.

Power spectral density was calculated using the short-time Fourier transform with a Hamming window of 1 s, without overlap, and was normalized by the total power of the signal up to 300 Hz. Coherence between the STN and the globus pallidus LFP recordings was estimated using Welch’s averaged modified periodogram method with non-overlapping Hamming windows (Welch, 1967; Rabiner and Gold, 1975). Window length was set to a second, giving rise to a frequency resolution of 1 Hz.

**Instantaneous beta phase and envelope**

LFPs were band-pass filtered ±2 Hz around the frequency exhibiting the highest STN-GP coherence in the beta band using a second order Butterworth filter applied forwards and backwards. Instantaneous beta envelope and instantaneous beta phase were estimated using the Hilbert Transform. Instantaneous beta envelope was derived using: $A(t) = \sqrt{x(t)^2 + |H(x(t))|^2}$, where $x(t)$ is the band-pass filtered LFP and $H(x(t))$ is the Hilbert Transform of the band-pass filtered LFP. Instantaneous phase was obtained using: $\Phi(t) = \arctan(H(x(t)), x(t))$ (Marple, 1999; Cagnan et al., 2013, 2014).

**Phase synchrony index between the STN and the pallidal beta activities**

The phase relationship between the globus pallidus and the STN beta activities was captured using the phase synchrony index (PSI) (Mehta et al., 2014). PSI is defined as $|\Sigma e^{i(\Phi_{GP} - \Phi_{STN})}|$ where $\Phi_{GP}$ and $\Phi_{STN}$ stand for the instantaneous phase of the beta activity in the globus pallidus and the STN, respectively. Summation is performed in time.

**Relationship between STN-GP phase difference and beta envelope**

To investigate the relationship between the phase difference between beta activities in the STN and the globus pallidus, and changes in beta envelope, we divided the percentage change in beta envelope (with respect to the median beta amplitude envelope observed throughout the recording) into 20 bins depending on the corresponding phase difference between the STN and the globus pallidus (Fig. 1). For each recording (i.e. STN and globus pallidus LFPs), 1000 surrogate time series were generated by computing the Fourier transform of the original time series, resampling phase without replacement while keeping the modulus of the time series unchanged and applying the inverse Fourier transform in order to return to the time domain. The phase difference–beta envelope relationship was then estimated in the surrogate time series and the threshold for significant modulation was set at 2.5th and 97.5th percentile of the beta envelope modulation obtained from the surrogate pairs. For each phase difference bin, if the median beta amplitude change observed at that bin was greater than the 97.5th percentile of the beta amplitude change in the surrogate time series then this phase bin was classified as ‘amplifying’. Similarly, if the median beta amplitude change observed at that bin was less than the 2.5th percentile of the beta amplitude change in the surrogate time series then the

**Table 1 Clinical details**

| Patient | Age and gender | Disease duration | UPDRS OFF/ON medication | L-DOPA challenge | Daily dose (mg) |
|---------|----------------|------------------|------------------------|------------------|-----------------|
| 1       | 39/M           | 7                | 80/15                  | 200 mg           | Levodopa 1300,  Ropinirole 4 |
| 2       | 64/M           | 10               | 51/8                   | 200 mg           | Levodopa 900    |
| 3       | 64/M           | 9                | 56/20                  | 200 mg           | Levodopa 1000,  Ropinirole 6 |
| 4       | 49/F           | 17               | 80/12                  | 200 mg           | Levodopa 1500,  Ropinirole 1.5 |
| 5       | 37/M           | 10               | 65/7                   | 200 mg           | Levodopa 150, Ropinirole 4 |

UPDRS = Unified Parkinson’s Disease Rating Scale.
phase bin was classified as ‘suppressive’. Remaining phase bins were classified as baseline.

**Group dependency of beta envelope on the STN-GP phase difference**

Phase difference–beta envelope profiles (Fig. 1) were averaged across the five subjects in order to obtain the average phase difference–beta envelope profile across all patients. To this end, each phase difference–beta envelope profile was realigned so that 0 radians corresponded to the phase difference affording maximal beta amplification OFF dopamine for that subject. Average STN-GP phase difference–LFP beta amplitude profiles obtained from OFF levodopa recordings were compared to those obtained following levodopa challenge using repeated measures ANOVA.

**Duration of locking to amplifying and suppressive phase differences**

For each patient, phase differences between the STN and the globus pallidus were separated according to whether the median beta modulation at this phase difference was classified as beta amplification, suppression or unchanged (i.e. baseline). No change, amplification and suppression were determined with respect to the beta modulation levels observed in the surrogate time series as described above. This classification was used in order to derive start, cessation and total duration of any amplifying/suppressive phase locking periods between the two nuclei. Amplifying or suppressive phase locking durations < 50 ms (i.e. one beta cycle) were not classified as phase locking and were considered part of the baseline.

**Amplification and suppression**

STN-GP phase difference–beta envelope profiles (Figs 1 and 2) tell us the instantaneous effect of a certain phase relationship between the STN and the globus pallidus on the local beta synchrony but do not capture the cumulative effect of locking to an amplifying or suppressive phase difference for a certain period of time. Using the classification outlined above, we investigated the effect of locking duration on the globus pallidus and the STN beta activities. Percentage changes in the beta amplitude envelope were grouped according to the total duration an amplifying or a suppressive phase difference was sustained between the STN and the globus pallidus. Repeated measures ANOVAs were used to quantify the effects of medication state and phase locking duration on median change in beta amplitude envelope. Because the distribution of phase-locking durations cannot be matched between patients and across medication states, for beta amplification, we divided all variables analysed into phase-locking duration bins of 20 ms long between 50 ms and 500 ms. Bins containing < 10 instances per subject were disregarded to ensure a reliable average per bin per patient. Phase locking duration bins common to all patients and drug states were used in repeated measures ANOVAs (i.e. five bins centred at 60 ms till 120 ms for beta amplification and two bins centred at 60 ms till 80 ms for beta suppression).

**Beta envelope correlation when STN and globus pallidus phase-locking**

To assess changes in effective connectivity when STN and globus pallidus lock to beta amplifying or suppressive phase differences, we computed the Spearman’s rank correlation between the STN and the globus pallidus beta amplitude envelopes across all segments with a phase-locking event. Data were realigned to termination of phase-locking events (i.e. phase-locking cessation). Phase-locking cessation was defined as the time point a phase-locking event (as defined above) of at least 50 ms long ended. Spearman’s rank correlation was computed across 62.5 ms long, non-overlapping windows around these events.

**Results**

**Exemplar relationship between STN-GP phase difference and local beta synchrony**

The predominant connectivity between STN and globus pallidus is a direct, monosynaptic, excitatory input from STN to globus pallidus. We can therefore consider the impact of beta activity in the STN on that in globus pallidus...
The globus pallidus beta activities was 0.39 OFF levodopa. The PSI between STN and globus pallidus beta activities acquired from the two neural nuclei were not uniformly distributed (Fig. 1C), but demonstrated preference for those STN-GP phase differences half a cycle displaced around \pi to 1 radians associated with amplification of both globus pallidus and STN beta activities (Fig. 1A and B). This preference can be formally assessed in terms of the phase synchrony observed in the surrogate time series. Amplifying and suppressive phase difference durations maintained for a duration of 50 ms or more are expressed as a % of the total recording time. Amplifying and suppressive phase durations are derived from the classification of phase differences inducing a significant change in beta levels with respect to the surrogate time series.

**PSI and dependency of local beta synchrony on the STN-GP phase difference at the group level**

Across the five patients, the PSI OFF levodopa was significantly greater than that ON levodopa (two-tailed paired Student’s t-test \( P = 0.011, \ dF = 4; \) Table 2). Figure 2 shows group averaged realigned variations in the beta amplitude with respect to STN-GP phase difference ON and OFF levodopa. This confirms that phase differences between STN and globus pallidus beta activities, which correspond to high and low local beta synchrony, are displaced by half a cycle. In keeping with the single subject data in Fig. 1, the group data also confirm that the modulation of amplitude by the STN-GP phase difference was greater OFF levodopa compared to ON levodopa (STN beta level: effect of drug state \( P = 0.045, \ dF = 1, \ F = 8.235; \) effect of phase difference \( P < 0.0001, \ dF = 19, \ F = 26; \) interaction between drug state and phase difference \( P < 0.0001, \ dF = 19, F = 11; \) globus pallidus beta level: effect of drug state \( P = 0.026, \ dF = 1, F = 12; \) effect of phase difference \( P < 0.0001, \ dF = 19, F = 43; \) interaction between drug state and phase difference \( P < 0.0001, \ dF = 19, F = 7; \) repeated measures ANOVAs).

Phase synchronies between activities in the two nuclei that were higher than those observed in surrogate time series are indicated as bold in Table 2 (OFF and ON levodopa). Significant PSI with respect to the surrogate time series is defined as PSI values greater than 97.5th percentile of the phase synchrony observed in the surrogate time series (\( n = 1000 \)). Amplifying and suppressive phase difference durations maintained for a duration of 50 ms or more are expressed as a % of the total recording time. Amplifying and suppressive phase durations are derived from the classification of phase differences inducing a significant change in beta levels with respect to the surrogate time series.

**Duration of phase-locking**

Figures 1 and 2 quantify changes in the instantaneous beta amplitude envelope at certain phase differences between the STN and globus pallidus LFP beta activities. Although ON levodopa phases were less likely to be in the region associated with increases in the beta amplitude envelope, even when phases were matched between ON and OFF medication, the beta amplifying effect was still diminished ON levodopa. One potential explanation might be that it is not only the instantaneous phase that dictates the changes...
in local beta synchrony, but also the duration over which such a phase has been sustained (Cagnan et al., 2013). To test this hypothesis we first investigated whether periods of phase-locking to amplifying or suppressive phases were prolonged OFF levodopa, and then whether amplitude amplifying or suppressing effects accumulated the longer a given phase was maintained. Accordingly, we first isolated data segments where the phase differences between the STN and globus pallidus were on average associated with amplification or suppression of the globus pallidus beta envelope with respect to the median globus pallidus beta envelope over the whole recording (Fig. 1A) (across all patients, phase differences which amplified globus pallidus beta amplitude also amplified STN beta amplitude as demonstrated in Fig. 1, therefore time periods identified based on globus pallidus beta activity have the same effect on the STN beta activity). Across the five patients, on average STN and globus pallidus locked to beta amplifying phase differences for a duration of 50 ms or more for 35% of the total recording OFF levodopa, and 18% ON levodopa ($P = 0.01; \text{dF} = 4; \text{two sided paired Student’s } t\text{-test}; \text{Table 2}). This difference was even more pronounced when phase-locking durations of 100 ms or more were considered; the two nuclei phase-locked to beta amplification for 17% of the total recording OFF levodopa, and 6.4% ON levodopa ($P = 0.0017; \text{dF} = 4; \text{two-sided paired Student’s } t\text{-test})

Table 2 Phase synchrony index between STN and globus pallidus beta activities and the total duration beta activities lock to beta-amplifying or suppressive phase differences OFF and ON levodopa

| Case | PSI OFF | PSI ON | Amplification duration OFF | Amplification duration ON | Suppression duration OFF | Suppression duration ON |
|------|--------|-------|-----------------------------|---------------------------|-------------------------|-------------------------|
| 1    | 0.55   | 0.18  | 42                          | 30                        | 18                      | 18                      |
| 2    | 0.33   | 0.25  | 31                          | 25                        | 19                      | 23                      |
| 3    | 0.58   | 0.16  | 36                          | 14                        | 17                      | 5                       |
| 4    | 0.29   | 0.07  | 29                          | 1                         | 11                      | 0                       |
| 5    | 0.39   | 0.13  | 36                          | 20                        | 21                      | 8                       |
| Mean ± SEM | 0.40 ± 0.05 | 0.16 ± 0.03 | 34 ± 2           | 18 ± 5                     | 17 ± 2                   | 11 ± 4                  |

Next we tested whether beta amplification is more marked the longer optimal phase differences between the STN and globus pallidus for beta amplification are sustained. We quantified the median change in beta amplitude in periods of locking to phases favouring amplification were both more prolonged and more frequent OFF levodopa.

### Increasing amplification with prolonged phase-locking

Next we tested whether beta amplification is more marked the longer optimal phase differences between the STN and globus pallidus for beta amplification are sustained. We quantified the median change in beta amplitude in...
successive 20 ms duration bins as time elapsed in phase-locking segments of progressively increasing length. This was performed up to the longest phase-locking duration that four recordings shared OFF and ON levodopa (i.e. 50 ms up to 130 ms). One subject did not exhibit significant amplification of beta ON dopamine and was not included in the repeated measures ANOVA analysis (Fig. 4A). We observed that globus pallidus beta power increased significantly as the duration of locking to amplifying phases increased (effect of locking duration: $P < 0.0001$, $dF = 3$, $F = 17$, effect of drug state: $P = 0.018$, $dF = 1$, $F = 22$, interaction between locking duration and drug state: $P = 0.26$, $dF = 3$, $F = 1.8$, repeated measures ANOVA). The effect of locking duration on degree of beta amplification in globus pallidus was linear (within subject contrast-effect of locking duration: $P = 0.007$, $dF = 1$, $F = 43$, repeated measures ANOVA). Thus, over the range explored in Fig. 4A, amplitude increased proportionately with the duration over which optimal amplifying phase differences between STN and globus pallidus were maintained. Accordingly, levodopa acts to diminish beta power by reducing the time spent with STN and globus pallidus activities locked to phases promoting amplitude increases. The latter is important because increases in beta amplitude accumulate. In Fig. 1 those instances with optimal phase for amplification ON levodopa are less likely to have been prolonged, explaining why their amplifying effect was less.

Just why should amplitude effects accumulate? Two principal possibilities exist. First, it could be that synaptic connections undergo strengthening over time when particular phases are maintained. This could reasonably be considered a form of spike-timing plasticity, but the durations of locking involved are rather brief for this mechanism. Alternatively, perhaps the cumulative effect is due to the progressive synchronization of an increasing field of neurons. Progressive increases in LFP amplitude while phase differences are maintained could then be considered to reflect a beta propagation wave within the nucleus. Such a wave might arise in globus pallidus in response to input at optimal phase from STN, but could equally arise in STN or in structures projecting to STN, with the temporal sequence then being passively transmitted onto the globus pallidus. In the latter case we would expect to see a very similar accumulation of amplitude amplification with increasing durations of phase-locking at amplifying phases within the STN as in globus pallidus. Figure 4B confirms that this was the case. As STN and globus pallidus locked to amplifying phases for long periods of time, the STN beta amplitude envelope increased (effect of locking duration: $P = 0.024$, $dF = 3$, $F = 5$, effect of drug state: $P = 0.3$, $dF = 1$, $F = 1.2$, interaction between locking duration and drug state: $P = 0.3$, $dF = 3$, $F = 1.6$, repeated measures ANOVA). These results suggest that although the amplification of beta amplitude in globus pallidus increases as the duration of locking at optimal phase differences for amplification extends, this is driven, at least in part, by a parallel phenomenon in STN.

**Suppression with prolonged phase-locking**

The duration of phase-locking to phase differences that promote beta suppression did not have an effect on how much the amplitude of beta band activity was suppressed (globus pallidus beta amplitude: effect of locking duration $P = 0.6$, $dF = 1$, $F = 0.2$, effect of medication state $P = 0.035$, $dF = 1$, $F = 13$, interaction between locking duration and dopamine $P = 0.3$, $dF = 1$, $F = 1.4$; STN beta amplitude: effect of locking duration $P = 0.4$, $dF = 1$, $F = 1$, effect of medication state $P = 0.07$, $dF = 1$, $F = 7.6$, interaction between locking duration and dopamine $P = 0.8$, $dF = 1$, $F = 0.05$, repeated measures ANOVAs). Suppression for a certain phase-locking duration was greater OFF dopamine with respect to ON dopamine in globus pallidus.

**Amplitude changes induced by phase-locking are correlated across nuclei and abruptly terminated**

We sought further evidence that changes in LFP amplitude in globus pallidus upon phase-locking between STN and globus pallidus closely relate to parallel amplitude changes

---

**Figure 4** Globus pallidus and STN beta amplitudes increase as the globus pallidus and STN beta activities lock to amplifying phase differences for longer periods of time. (A) Beta accumulation in the globus pallidus with increasing phase-locking duration, each bar is averaged across four subjects (black: OFF dopamine; red: ON dopamine); (B) beta accumulation in the STN with increasing phase-locking duration, each bar is averaged across four subjects (black: OFF dopamine; red: ON dopamine). The x-axis labels indicate centre of locking duration bins.
Discussion

It has been previously suggested that the instantaneous effective connectivity between different cortical regions depends on the phase alignment between their intrinsic activities, a theory termed communication-through-coherence (Fries, 2005, 2009; Womelsdorf et al., 2007). Thus, for an excitatory connection there will be a phase difference at which one region will optimally excite another. This dynamic modulation of effective connectivity should exist even if the mean firing rate of the input to the second neuronal population remains unchanged. Here, we extend the reach of this seminal hypothesis to subcortical domains, whilst furnishing evidence that persistent maximal effective connectivity during optimal phase alignment might lead to diminished system performance, as evinced by motoric impairment. More dynamic phase alignment is promoted by restoration of dopaminergic input, and with improvement in motoric performance.

We show that the degree of local (i.e. predominantly intra-nuclear) beta synchrony is modulated by the distribution of phase differences between the STN and the globus pallidus, and by how long specific phase differences are maintained. Phase differences can be biased to beta-amplifying phases, as in Parkinson’s disease patients withdrawn from their dopaminergic medication, or more evenly distributed, as following administration of the dopamine pro-drug, levodopa. Once the STN-GP circuit settles on a beta-amplifying phase relationship, the degree of amplification depends upon how long this phase relationship is maintained. Specifically amplification effects accumulate, and so effective connectivity can be strengthened by having more prolonged periods of coupling at phase...
differences that amplify the envelop of beta oscillations. While the degree of amplification for a certain period of coupling is the same ON and OFF dopamine, instances of coupling that amplify beta are more prolonged and more frequent in Parkinson’s disease patients withdrawn from their dopaminergic medication compared to following treatment with levodopa.

Thus, the STN-GP circuit is biased towards strengthened local beta synchrony and enhanced effective connectivity in the relative absence of dopaminergic input to the basal ganglia. It is in this state that motor function is most compromised, and a reasonable inference is that effective connectivity is so strengthened that dynamic task-related variation in connectivity is impaired and ‘the system is jammed open’. This would be in-line with the view that excessive phase synchronization can lead to loss of information coding capacity and failure in information transfer in the basal ganglia, thereby compromising behaviour (Dethier et al., 2013; Brittain and Brown, 2014).

Signal-to-noise ratios

It should be borne in mind that the detection of phase is dependent on signal-to-noise ratios, leading to the possible overestimation of phase slips in the ON medication, low-beta power state. However, it is unlikely that measurement noise, including any unreliability of our algorithm for estimating phase, could explain all of our findings. Despite the potentially lower beta power in the ON medication state, phase synchrony differed from that of surrogates in this condition (Table 2). The same condition also showed phase-locking duration-dependent, amplitude-enhancing effects. Indeed, relative phase distributions and phase-dependent, amplitude enhancing effects observed ON medication were little different to those in the OFF drug, high-beta power state (Fig. 4).

Phase slips

One of the most important factors limiting exaggerated effective connectivity is restriction of the duration over which phase differences may settle at values promoting amplitude amplification. The events leading to interruption of phase-locking have previously been termed ‘phase slips’ (Hurtado et al., 2005). In principle, the increase in phase slips ON dopamine could be related to changes in membrane properties (Park and Rubchinsky, 2012a, b), and their secondary effects, especially frequency mismatch between oscillating neurons or collections of neurons (Ermentrout and Rinzel, 1984). Indeed, in a recent study, we demonstrated that phase-specific changes in amplitude reflect the degree of tuning of a network’s resonance function (Cagnan et al., 2014). The reduction in phase-specific beta amplitude modulation following treatment of Parkinson’s disease patients with levodopa suggests that the pathologically narrow frequency tuning of the basal ganglia network in Parkinson’s disease is broadened by dopaminergic input. Dopamine’s transient depolarization induced inactivation of T-type calcium channels in STN neurons may contribute to this shift away from narrow tuning by switching STN neurons from burst mode to a tonic mode (Dethier et al., 2013). This would potentially shift the subthalamic neurons into a state that is no longer capable of sustaining beta oscillations in the GP-STN network.

Some of the other processes that might contribute to phase slips in the basal ganglia include resetting by cortical inputs (Doyle Gaynor et al., 2008) and spike-time dependent depression (Ahn and Rubchinsky, 2013). Together these diverse biological processes in effect increase biological, as opposed to measurement, noise (Ahn et al., 2011). These processes need not exclusively be under dopaminergic control. However, the changes detected between medication states do suggest at least some influence of dopamine. Phase slips induced by biological noise have already been proposed to be a feature of physiological connectivity in the beta frequency band at the cortical level (Ahn and Rubchinsky, 2013), and our results suggest that this may also be the case within the basal ganglia, under the influence of multiple processes, some modulated by dopamine.

Active decorrelation

The data also revealed another important factor limiting excessive synchronization within the two nuclei. As well as locking to phases promoting local synchrony in beta, periods of relatively consistent phase-locking could also occur at phases promoting beta suppression, as anticipated by Womelsdorf et al. (2007) with respect to gamma interactions at the cortical level. Importantly, in the present data these periods were associated with decorrelation between the amplitude envelopes of the beta LFP activities in STN and globus pallidus OFF levodopa. Thus, phase alignment between functionally connected nuclei could decrease as well as increase information exchange as indexed by amplitude correlation between the two regions OFF levodopa. What might underpin these decorrelating events is uncertain. However, distinct phase differences between the basal ganglia nuclei that induce increased correlation and those that decorrelate raises the possibility of dynamic shifts between completing connections with different conduction delays and timings; potentially instantiated by the direct and indirect pathways (Bolam et al., 2000).

Synchronization as a function of resonance

A notable feature of the current results is that the cumulative amplitude amplification seen with longer duration locking at phase differences associated with increases in amplification was already present at the level of the STN. The data are consistent with a spreading wave of beta-band synchronization within the STN, or in structures projecting to STN, with the temporal sequence then spilling over to
Recent modelling studies have stressed how effective connectivity, particularly that promoted by specific phase differences between oscillating neurons or collections of neurons, can be an emergent property of coupled neural oscillators when they are either driven by rhythmic activity at their resonance frequency or when they receive tonic excitation that pushes them to oscillate at the resonant frequency (Hahn et al., 2014). In this regard, it is interesting that the phase differences in the beta frequency band between STN and globus pallidus preferentially assumed those values that promoted intranucleus and internuclei coherence, consistent with what has been termed emergent ‘coherence-through-resonance’ (Hahn et al., 2014). Indeed it may take several cycles for such ‘coherence-through-resonance’ to be established, consistent with the accumulating increase in the globus pallidus LFP amplitude envelop when optimal STN-GP phase differences were sustained for up to three to four cycles. A similar delayed increase in local beta power has previously been reported during inter-areal phase synchronization at the cortical level (Tallon-Baudry et al., 2001). A picture emerges of recurrent spreading waves of beta-band synchronization within the STN, each terminated by a phase slip. These waves occur more frequently OFF levodopa, possibly in response to inputs that promote dynamic episodes of intra- and internuclear resonance in the beta band with feed-forward coherence being established as an emergent phenomenon of such resonance. Importantly, beta-band synchronization within the subthalamic region of patients with Parkinson’s disease involves phase differences that are compatible with a spreading phenomenon within the STN region and limited to the beta frequency band (Pogosyan et al., 2010). Moreover, several experimental studies already point to beta-band resonance in the basal ganglia-cortical loop, as evidenced by the transient beta oscillations in the STN following cortical stimulation (Magill et al., 2004, 2006), oscillations at the cortical level following low frequency stimulation of the STN (Eusebio et al., 2009), and the reverberant activity in the STN-GP externa circuit (Mallet et al., 2008).

**Figure 6** Schematic of STN-globus pallidus coupling. Phase of individual neurons shown by black arrows. Phase difference in STN-GP coupling is optimal when neurons in each nucleus share the same phase (shown by upward pointing black arrows). Phase synchronized neurons are connected by blue lines within a nucleus and grey arrows between nuclei. Below each nucleus schematic is one of the beta-band LFP in red, demonstrating that this increases in amplitude while optimal phase for amplitude amplification is maintained, and is then suppressed again following a phase slip.

**Implications for therapy**

Our results point to intermittent increases in effective connectivity between STN and globus pallidus activities even at rest. When dopaminergic input is diminished, these dynamic events involve a greater likelihood of prolonged locking to phases promoting amplification, thereby contributing to the excessive network beta synchrony that is a key feature of Parkinson’s disease (Hammond et al., 2007). Importantly, however, episodes of exaggerated network synchrony are punctuated by lesser degrees of synchrony even in untreated Parkinson’s disease. It is the assumption that interleaved periods of less exaggerated network synchrony might allow more physiological processing that motivates temporally selective adaptive deep brain stimulation strategies (Little and Brown, 2012). Leaving these interleaved periods of reduced synchrony undisturbed by stimulating the STN only when a certain level of beta activity is exceeded may provide better motor improvement than continuous high frequency stimulation (Little et al., 2013). Moreover the current results highlight another phenomenon that might be beneficially spared with adaptive deep brain stimulation based on beta LFP amplitude; periods of phase-locking of the STN and globus pallidus at phases promoting amplitude suppression and decorrelation. The shift to a relative preponderance of phases promoting amplitude suppression might, in combination with any synaptic depotentiation effect of interactions with these phase relations, help explain why beta power drops over time during sustained adaptive deep brain stimulation (Little et al., 2013).

However, the present findings suggest a further means by which adaptive deep brain stimulation might be made potentially more efficient and selective. The precise phase alignment between STN and globus pallidus appears to
be crucial for the amplification of beta. Thus, by tracking the phase of LFP oscillations in the STN or globus pallidus one can potentially stimulate to shift the instantaneous phase of the local neuronal population activity (Tass and Majtanik, 2006; Cagnan et al., 2014) away from that promoting further coupling and amplitude increases and towards that promoting amplitude suppression. This could potentially reverse excessive synaptic coupling within the basal ganglia in a targeted and controlled manner.

**Conclusion**

Our data point to a pathologically exaggerated resonant state in untreated Parkinson's disease that allows the progressive propagation of beta synchrony through basal ganglia nuclei like the STN and globus pallidus, and the settling of coupled oscillators into a regime in which phase differences between them preferentially assume values that favour further feed-forward amplitude amplification in the circuit. The circuit is ‘jammed open’ with diminished capability for task-related variation in effective connectivity. Under more physiological conditions circuit resonances in the beta band are lessened and the settling of coupled oscillators into phase regimes that favour amplitude amplification is more likely to be terminated earlier by phase slips. Dopamine promotes these processes, biasing basal ganglia circuit behaviour away from exaggerated synchronization within and between nuclei, and increasing the dynamic range of moment-to-moment task related variation in effective connectivity. This dynamic modulation of effective connectivity occurs orthogonal to changes in effective connectivity engendered through increases or decreases in the average firing rate of the STN. The relationship between these two means of information transfer remains an unresolved but key issue in our understanding of the primary and secondary network changes underlying Parkinson’s disease.

**Acknowledgements**

We are grateful to Prof. P. Mazzone and Prof. V. Di Lazzaro for their help with the original recordings.

**Funding**

This study was funded by the National Institute of Health Research, Oxford Biomedical Research Centre, Medical Research Council and Wellcome Trust.

**References**

Ahn S, Park C, Rubchinsky LL. Detecting the temporal structure of intermittent phase locking. Phys Rev E 2011; 84: 016201.
Ahn S, Rubchinsky LL. Short desynchronization episodes prevail in synchronous dynamics of human brain rhythms. Chaos Interdiscip. J. Nonlinear Sci 2013; 23: 013138.

Bolam JP, Hanley JJ, Booth PAC, Bevan MD. Synaptic organisation of the basal ganglia. J Anat 2000b; 196: 527–42.
Brittain JS, Brown P. Oscillations and the basal ganglia: motor control and beyond. Neuroimage 2014; 85 (Pt 2): 637–47.
Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Lazzaro VD. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s Disease. J Neurosci 2001; 21: 1033–8.
Buzsáki G, Draguhn A. Neuronal oscillations in cortical networks. Science 2004; 304: 1926–9.
Cagnan H, Brittain J-S, Little S, Foltynie T, Limousin P, Zrinzo L, et al. Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation. Brain 2013; 136: 3062–73.
Cagnan H, Little S, Foltynie T, Limousin P, Hariz M, Chee ran B, et al. The nature of central oscillator circuits in parkinsonian and essential tremor. Brain 2014; 137: 3223–34.
Cassidy M, Mazzone P, Oliviero A, Insola A, Tonali P, Di Lazzaro V, et al. Movement-related changes in synchronization in the human basal ganglia. Brain 2002; 125: 1235–46.
Dethier J, Drion G, Franci A, Sepulchre R. Modulation of beta oscillations during movement initiation: modeling the ionic basis of a functional switch [Internet]. ArXiv:1311.2238.
Doyle Gaynor LMF, Kuhn AA, Dileone M, Litvak V, Eusebio A, Pogosyan A, et al. Suppression of beta oscillations in the subthalamic nucleus following cortical stimulation in humans. Eur J Neurosci 2008; 28: 1686–95.
Ermentrout GB, Rinzel J. Beyond a pacemaker’s entrainment limit: phase walk-through. Am J Physiol Regul Integr Comp Physiol 1984; 246: R102–6.
Eusebio A, Pogosyan A, Wang S, Averbeck B, Gaynor LD, Cantiniaux S, et al. Resonance in subthalamo-cortical circuits in Parkinson’s disease. Brain J Neurol 2009; 132: 2139–50.
Fogelson N, Pogosyan A, Kuhn AA, Kupsch A, Van Bruggen G, Speelman H, et al. Reciprocal interactions between oscillatory activities of different frequencies in the subthalamic region of patients with Parkinson’s disease. Eur J Neurosci 2005; 22: 257–66.
Fries P. A mechanism for cognitive dynamics: neuronal communication through neuronal coherence. Trends Cogn Sci 2005; 9: 474–80.
Fries P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Ann Rev Neurosci 2009; 32: 209–24.
Hahn G, Bujan A, Fregnac Y, Aertsen A, Kumar A. Communication through resonance in spiking neuronal networks. PLoS Comput Biol 2014; 10: e1003811.
Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson’s disease: networks, models and treatments. Trends Neurosci 2007; 30: 357–64.
Hirschmann J, Ozkurt TE, Butz M, Homburger M, Elben S, Hartmann CJ, et al. Distinct oscillator STN-cortical loops revealed by simultaneous MEG and local field potential recordings in patients with Parkinson’s disease. NeuroImage 2011; 55: 1159–68.
Hurtado JM, Rubchinsky LL, Sigvardt KA, Wheelock VL, Pappas CTE. Temporal evolution of oscillations and synchrony in GPi/muscle pairs in Parkinson’s disease. J Neurophysiol 2005; 93: 1569–84.
Kuhn AA, Kupsch A, Schneider G-H, Brown P. Reduction in subthalamic 8–35 Hz oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur J Neurosci 2006; 23: 1956–60.
Kuhn AA, Trottenberg T, Kivi A, Kupsch A, Schneider G-H, Brown P. The relationship between local field potential and neuronal discharge in the subthalamic nucleus of patients with Parkinson’s disease. Exp Neurol 2005; 194: 212–20.
Kuhn AA, Tsai A, Aziz T, Ray N, Brücke C, Kupsch A, et al. Pathological synchronisation in the subthalamic nucleus of patients with Parkinson’s disease relates to both bradykinesia and rigidity. Exp Neurol 2009; 215: 380–7.
Levy R, Hutchison WD, Lozano AM, Dostrovsky JO. Synchronized neuronal discharge in the basal ganglia of parkinsonian patients is limited to oscillatory activity. J Neurosci 2002; 22: 2855–61.
Little S, Brown P. What brain signals are suitable for feedback control of deep brain stimulation in Parkinson’s disease? Ann N Y Acad Sci 2012; 1265: 9–24.

Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol 2013; 74: 449–57.

Litvak V, Jha A, Eusebio A, Oostenveld R, Foltynie T, Limousin P, et al. Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson’s disease. Brain J Neurol 2011; 134: 359–74.

Magill PJ, Sharott A, Bevan MD, Brown P, Bolam JP. Synchronous Unit activity and local field potentials evoked in the subthalamic nucleus by cortical stimulation. J Neurophysiol 2004; 92: 700–14.

Magill PJ, Sharott A, Bolam JP, Brown P. Delayed synchronization of activity in cortex and subthalamic nucleus following cortical stimulation in the rat. J Physiol 2006; 574: 929–46.

Mallet N, Pogosyan A, Mar´ton LF, Bolam JP, Brown P, Magill PJ. Parkinsonian beta oscillations in the external globus pallidus and their relationship with subthalamic nucleus activity. J Neurosci 2008; 28: 14245–58.

Marple SLJ. Computing the discrete-time “analytic” signal via FFT. IEEE Trans Signal Process 1999; 47: 2600–3.

Marreiros AC, Cagnan H, Moran RJ, Friston KJ, Brown P. Basal ganglia–cortical interactions in Parkinsonian patients. NeuroImage 2013; 66: 301–10.

Mehta A, Brittain J-S, Brown P. The selective influence of rhythmic cortical versus cerebellar transcranial stimulation on human physiological tremor. J Neurosci 2014; 34: 7501–8.

Park C, Rubchinsky LL. Potential mechanisms for imperfect synchronization in parkinsonian basal ganglia. PLoS One 2012b; 7: e51530.

Peppe A, Pierantozzi M, Bassi A, Alibrandi MG, Brusa L, Stefani A, et al. Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. J Neurosurg 2004; 101: 195–200.

Pogosyan A, Yoshida F, Chen CC, Martinez-Torres I, Foltynie T, Limousin P, et al. Parkinsonian impairment correlates with spatially extensive subthalamic oscillatory synchronization. Neuroscience 2010; 171: 245–57.

Rabiner LR, Gold B. Theory and application of digital signal processing [Internet]. Englewood Cliffs, NJ: Prentice-Hall Inc, 1975. p. 777.

Ray NJ, Jenkinson N, Wang S, Holland P, Brittain J-S, Joint C, et al. Local field potential beta activity in the subthalamic nucleus of patients with Parkinson’s disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation. Exp Neurol 2008; 213: 108–13.

Tallon-Baudry C, Bertrand O, Fischer C. Oscillatory synchrony between human extrastriate areas during visual short-term memory maintenance. J Neurosci 2001; 21: RC177: 1–5.

Tass PA, Majtanik M. Long-term anti-kindling effects of desynchronizing brain stimulation: a theoretical study. Biol Cybern 2006; 94: 58–66.

Weinberger M, Mahant N, Hutchison WD, Lozano AM, Moro E, Hodaie M, et al. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson’s disease. J Neurophysiol 2006; 96: 3248–56.

Welch PD. The use of fast Fourier transform for the estimation of power spectra: a method based on time averaging over short, modified periodograms. IEEE Trans Audio Electroacoustics 1967; 15: 70–3.

Williams D, Tijssen M, Van Bruggen G, Bosch A, Insola A, Di Lazzaro V, et al. Dopamine-dependent changes in the functional connectivity between basal ganglia and cerebral cortex in humans. Brain 2002; 125: 1558–69.

Womelsdorf T, Schoffelen J-M, Oostenveld R, Singer W, Desimone R, Engel AK, et al. Modulation of neuronal interactions through neuronal synchronization. Science 2007; 316: 1609–12.

Yang AI, Vanegas N, Lungu C, Zaghloul KA. Beta-coupled high-frequency activity and beta-locked neuronal spiking in the subthalamic nucleus of Parkinson’s disease. J Neurosci 2014; 34: 12816–27.